Metropolis Healthcare Ltd
NSE:METROPOLIS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Metropolis Healthcare Ltd
Gross Profit
Metropolis Healthcare Ltd
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Metropolis Healthcare Ltd
NSE:METROPOLIS
|
Gross Profit
₹12.3B
|
CAGR 3-Years
11%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Dr Agarwal's Eye Hospital Ltd
BSE:526783
|
Gross Profit
₹3.5B
|
CAGR 3-Years
21%
|
CAGR 5-Years
29%
|
CAGR 10-Years
13%
|
|
|
Thyrocare Technologies Ltd
NSE:THYROCARE
|
Gross Profit
₹5.8B
|
CAGR 3-Years
17%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Dr. Lal PathLabs Ltd
NSE:LALPATHLAB
|
Gross Profit
₹21.5B
|
CAGR 3-Years
11%
|
CAGR 5-Years
15%
|
CAGR 10-Years
14%
|
|
|
Vijaya Diagnostic Centre Ltd
NSE:VIJAYA
|
Gross Profit
₹5.8B
|
CAGR 3-Years
14%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Krsnaa Diagnostics Ltd
NSE:KRSNAA
|
Gross Profit
₹5.3B
|
CAGR 3-Years
10%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
Metropolis Healthcare Ltd
Glance View
Metropolis Healthcare Ltd., a pioneer in the diagnostics industry, embarked on its journey in 1980 under the visionary leadership of Dr. Sushil Kanubhai Shah. This Mumbai-based company quickly established itself as a trusted name, offering a comprehensive range of diagnostic services, including pathology tests, radiology, and wellness solutions. The heart of its operations lies in its expansive network of laboratories and collection centers strategically distributed across India and several international locations. By leveraging state-of-the-art technology and maintaining rigorous quality standards, Metropolis has positioned itself as a forerunner in providing precise and reliable medical test results. This was especially crucial as the demand for accurate healthcare diagnostics surged, driven by an increasingly health-conscious population. Metropolis generates its revenue primarily through fees charged for its broad spectrum of diagnostic tests that cater to a variety of health needs, from routine screenings to specialized, high-complexity tests. Its business model capitalizes on partnerships with healthcare providers, hospitals, and corporations, offering customized health packages and diagnostic solutions that ensure a steady flow of clientele. By integrating advanced testing technologies and continuously expanding its service portfolio, the company taps into diverse revenue streams, which include corporate wellness programs and home health services. This diversified approach not only enhances its financial stability but also solidifies its reputation as a go-to healthcare partner for individuals, corporate clients, and healthcare institutions alike.
See Also
What is Metropolis Healthcare Ltd's Gross Profit?
Gross Profit
12.3B
INR
Based on the financial report for Dec 31, 2025, Metropolis Healthcare Ltd's Gross Profit amounts to 12.3B INR.
What is Metropolis Healthcare Ltd's Gross Profit growth rate?
Gross Profit CAGR 5Y
13%
Over the last year, the Gross Profit growth was 18%. The average annual Gross Profit growth rates for Metropolis Healthcare Ltd have been 11% over the past three years , 13% over the past five years .